Brazilian origin species Enterolobium contortisiliquum (Vell.) Morong (Fabaceae) is distributed from north to south of the country. The species is a pioneer and important in the manufacture of furniture, boats and canoes, and presents easy handling also being significant for degraded areas recovery programs. As a result, management plans are necessary for the survival of this species. In the context of reforestation and recovery of degraded areas, the production of seedlings of native forest species occurs in nurseries and the quality of these plants depends on several factors, among which, the composition of the substrates is a factor of great importance for having its physical, chemical and biological characteristics directly linked to the growth of the seedlings. The study was based on obtaining knowledge and potential applicability in seedling production, subjecting it to different substrates, in order to evaluate their growth in height, diameter, number of leaves and biomass. The behavior presented by the species suggests its potential for reforestation turned to production and conservationism, since it revealed tolerance to the various types of substrates and better results with the use of organic matter added to the substrate.
The incidence of cancer has been increasing throughout Europe for decades. In 2003 in Austria, 36,689 people developed malignant tumours, that is 26.7% more than in 1986. In total, every third person will have cancer during their life-time. However the total number of people dying from cancer remains more or less constant. This is due to advances in diagnosis and treatment, almost one-third of the fall in mortality in the period from 1995-2003 being attributable to the use of modern anti-cancer medications. The cost factor related to modern cancer treatment is increasingly a subject for discussion. The aim of this research was to analyse hospital treatment costs and expenditure on medication in the oncology sector in a broader context. The intention was to show the costs of oncology in-patient treatment in relation to the overall Austrian hospital costs and health expenditure. Only in this way it is possible to establish whether the proportion spent on oncology is really disproportionately high. This analysis shows that despite increasing hospital admissions and the associated increase in treatment no cost explosion has taken place. The analysis of costs based on malignant tumours in relation to overall costs has shown that these are not disproportionately high even when taking the number of patients into account. Only 12.21% of cancer treatment costs are used for anti-cancer medications (ATC-classes L01 and L02). The proportion of anti-cancer medications related to the total hospital expenditure is approximately 1.04%. The costs of anti-cancer medication in the hospital sector have a ratio of 0.46% of health expenditure and 3.66% of Austrian expenditure on medications. This shows that based on the low proportion of the overall expenditure anti-cancer medications are not pushing up costs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.